FDA ques­tions da­ta on MD­MA-based ther­a­py in PTSD ahead of ad­vi­so­ry com­mit­tee

The FDA ques­tioned da­ta around Lykos Ther­a­peu­tics’ MD­MA-based ther­a­py for post-trau­mat­ic stress dis­or­der on Fri­day, less than a week be­fore its ad­vi­so­ry com­mit­tee meets to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.